Eczema drug interaction study: will rocatinlimab change how other meds work?
NCT ID NCT05891119
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase study looked at how rocatinlimab, an experimental drug for eczema, affects the way the body processes several common medications (caffeine, metoprolol, midazolam, warfarin, omeprazole). 21 adults with moderate to severe eczema took these drugs with and without rocatinlimab to measure any changes. The goal was to gather safety and interaction data, not to treat the eczema itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
rocatinlimab (AMG 451)
What this could lead to
If successful, this study could help doctors understand how rocatinlimab interacts with other medications, guiding safer use in future eczema treatments.
What could go wrong
This is a very early, small study (21 people) focused on drug interactions, not on treating eczema. It may not lead to any new treatment or change in care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accel Research Sites (ACR)
DeLand, Florida, 32720-3134, United States
-
Axis Clinicals, LCC
Dilworth, Minnesota, 56529, United States
-
DermDox Dermatology Centers, PC - Camp Hill
Camp Hill, Pennsylvania, 17011, United States
-
DermDox Dermatology Centers, PC - Sugarloaf
Nashville, Tennessee, 37203-1632, United States
-
Direct Helpers Research Center (DHRC)
Hialeah, Florida, 33012-3618, United States
-
Velocity Clinical Research -Spartanburg
Spartanburg, South Carolina, 29303-4225, United States
-
Velocity Clinical Research, North Hollywood
North Hollywood, California, 91606-1570, United States